Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (101-110 of 227) with videos related to

Pageof 23
Sort By:
Immunotherapy|November 8, 2023
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry studyJohn M Kirkwood, Lisa A Kottschade, Robert R McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell CarcinomaJean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
European Urology|February 11, 2011
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinomaKatherine M Krajewski, Mengye Guo, Annick D Van den Abbeele, et al.
Melanoma Research|September 1, 2018
Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patientsSally Y Tan, Julie Najita, Xiaoxue Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)Rana R McKay, Bradley A McGregor, Wanling Xie, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Clinical Genitourinary Cancer|April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
Journal for Immunotherapy of Cancer|December 22, 2022
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinomaBrian I Rini, Sabina Signoretti, Toni K Choueiri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint InhibitorsAnita Gul, Tyler F Stewart, Charlene M Mantia, et al.
The Oncologist|September 8, 2018
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell CarcinomaToni K Choueiri, M Dror Michaelson, Edwin M Posadas, et al.
Pageof 23

Showing results (101-110 of 227) with videos related to

Sort By:
Pageof 23
Immunotherapy|November 8, 2023
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry studyJohn M Kirkwood, Lisa A Kottschade, Robert R McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell CarcinomaJean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
European Urology|February 11, 2011
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinomaKatherine M Krajewski, Mengye Guo, Annick D Van den Abbeele, et al.
Melanoma Research|September 1, 2018
Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patientsSally Y Tan, Julie Najita, Xiaoxue Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)Rana R McKay, Bradley A McGregor, Wanling Xie, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Clinical Genitourinary Cancer|April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
Journal for Immunotherapy of Cancer|December 22, 2022
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinomaBrian I Rini, Sabina Signoretti, Toni K Choueiri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint InhibitorsAnita Gul, Tyler F Stewart, Charlene M Mantia, et al.
The Oncologist|September 8, 2018
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell CarcinomaToni K Choueiri, M Dror Michaelson, Edwin M Posadas, et al.
Pageof 23